Xeris Pharmaceuticals (NSDQ:XERS) said last week that it launched a Phase I trial of its ready-to-use liquid glucagon in a closed-loop, dual-hormone artificial pancreas system.
Automated insulin delivery systems represent the latest advancement in diabetes management. But these technologies fall short of performing the tasks of a human pancreas – they deliver insulin, but they can’t co-deliver glucagon. Traditional dry-powder glucagon formulations must be used immediately, according to Xeris, or else they begin to degrade.
Get the full story at our sister site, Drug Delivery Business News.
The post Xeris Pharmaceuticals kicks off dual-hormone artificial pancreas trial appeared first on MassDevice.